CN106687112A - 醋酸阿比特龙制剂和使用方法 - Google Patents

醋酸阿比特龙制剂和使用方法 Download PDF

Info

Publication number
CN106687112A
CN106687112A CN201580050453.8A CN201580050453A CN106687112A CN 106687112 A CN106687112 A CN 106687112A CN 201580050453 A CN201580050453 A CN 201580050453A CN 106687112 A CN106687112 A CN 106687112A
Authority
CN
China
Prior art keywords
abiraterone acetate
less
dose
sodium
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580050453.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·墨菲
P·内梅斯
H·W·伯士
M·卡拉汉
S·布哈米迪帕蒂
J·科勒曼
C·希尔
M·诺雷特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iceutica Inc
Original Assignee
Iceutica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55533897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106687112(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/707,922 external-priority patent/US20150246060A1/en
Application filed by Iceutica Inc filed Critical Iceutica Inc
Publication of CN106687112A publication Critical patent/CN106687112A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
CN201580050453.8A 2014-09-18 2015-09-18 醋酸阿比特龙制剂和使用方法 Pending CN106687112A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462052294P 2014-09-18 2014-09-18
US62/052,294 2014-09-18
US14/707,922 2015-05-08
US14/707,922 US20150246060A1 (en) 2013-03-15 2015-05-08 Abiraterone Acetate Formulation and Methods of Use
PCT/US2015/050889 WO2016044701A1 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use

Publications (1)

Publication Number Publication Date
CN106687112A true CN106687112A (zh) 2017-05-17

Family

ID=55533897

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580050453.8A Pending CN106687112A (zh) 2014-09-18 2015-09-18 醋酸阿比特龙制剂和使用方法

Country Status (17)

Country Link
EP (1) EP3193857A4 (enExample)
JP (1) JP2017528457A (enExample)
KR (2) KR102617537B1 (enExample)
CN (1) CN106687112A (enExample)
AP (1) AP2017009804A0 (enExample)
AU (1) AU2015317466A1 (enExample)
BR (1) BR112017003219A2 (enExample)
CA (1) CA2958316A1 (enExample)
CO (1) CO2017002472A2 (enExample)
EA (1) EA201790650A1 (enExample)
IL (1) IL250270B (enExample)
MD (1) MD20170048A2 (enExample)
MX (1) MX2017003525A (enExample)
PH (1) PH12017500239A1 (enExample)
SG (1) SG11201701139YA (enExample)
TN (2) TN2018000318A1 (enExample)
WO (1) WO2016044701A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110742870A (zh) * 2019-12-04 2020-02-04 武汉大学 醋酸阿比特龙制剂及其制备方法
CN111110646A (zh) * 2020-02-19 2020-05-08 纳兰迦(上海)生物医药科技有限公司 一种低规格醋酸阿比特龙口服制剂的处方及制备方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2863500T3 (es) 2015-04-10 2021-10-11 Capsugel Belgium Nv Formulaciones lipídicas de acetato de abiraterona
CA3061267A1 (en) 2017-04-07 2018-10-11 Maa Laboratories, Inc. Methods of improving the solubility and bioavailability of therapeutic agents
WO2020151633A1 (en) * 2019-01-25 2020-07-30 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions
EP3935068B1 (en) 2019-03-06 2023-09-06 Propella Therapeutics, Inc. Abiraterone prodrugs
CN113384542B (zh) * 2020-03-14 2024-03-29 鲁南制药集团股份有限公司 一种甾体cyp17抑制剂固体分散体的片剂及其制备方法
KR20220166856A (ko) * 2020-04-16 2022-12-19 타반타 테라퓨틱스 헝가리 인코포레이티드 전립선암을 치료하기 위한 방법 및 조성물
WO2021224469A1 (en) * 2020-05-08 2021-11-11 Janssen Pharmaceutica Nv Treatments of prostate cancer with combinations of abiraterone acetate and niraparib
EP3944860A1 (en) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
US11957696B2 (en) 2021-02-15 2024-04-16 Propella Therapeutics, Inc. Abiraterone prodrugs
KR20240044329A (ko) 2022-09-28 2024-04-04 한미약품 주식회사 아비라테론 아세테이트 및 프레드니솔론을 포함하는 경구용 복합정제
KR20240145412A (ko) 2023-03-27 2024-10-07 한미약품 주식회사 아비라테론 아세테이트 및 프레드니솔론을 포함하는 약제학적 제제 및 이의 제조방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013164473A1 (en) * 2012-05-04 2013-11-07 Jagotec Ag Pharmaceutical composition comprising abiraterone acetate
CN105246598A (zh) * 2013-03-15 2016-01-13 艾塞尤提卡公司 乙酸阿比特龙酯制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL254371B2 (en) * 2009-04-24 2023-09-01 Iceutica Pty Ltd Production of encapsulated nanoparticles on a commercial scale
WO2014009434A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014009437A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
CN102743393A (zh) * 2012-07-27 2012-10-24 海南盛科生命科学研究院 一种含有醋酸阿比特龙的药物组合物及制备工艺

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013164473A1 (en) * 2012-05-04 2013-11-07 Jagotec Ag Pharmaceutical composition comprising abiraterone acetate
CN105246598A (zh) * 2013-03-15 2016-01-13 艾塞尤提卡公司 乙酸阿比特龙酯制剂

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110742870A (zh) * 2019-12-04 2020-02-04 武汉大学 醋酸阿比特龙制剂及其制备方法
CN111110646A (zh) * 2020-02-19 2020-05-08 纳兰迦(上海)生物医药科技有限公司 一种低规格醋酸阿比特龙口服制剂的处方及制备方法

Also Published As

Publication number Publication date
MD20170048A2 (ro) 2017-08-31
CA2958316A1 (en) 2016-03-24
MX2017003525A (es) 2017-06-21
EA201790650A1 (ru) 2017-07-31
BR112017003219A2 (pt) 2017-11-28
IL250270A0 (en) 2017-03-30
AP2017009804A0 (en) 2017-03-31
IL250270B (en) 2021-02-28
EP3193857A1 (en) 2017-07-26
KR102617537B1 (ko) 2023-12-22
KR20230014878A (ko) 2023-01-30
AU2015317466A1 (en) 2017-02-23
TN2017000098A1 (en) 2018-10-19
CO2017002472A2 (es) 2017-07-11
WO2016044701A1 (en) 2016-03-24
TN2018000318A1 (en) 2020-01-16
JP2017528457A (ja) 2017-09-28
EP3193857A4 (en) 2018-04-11
KR20170070025A (ko) 2017-06-21
PH12017500239A1 (en) 2017-07-03
SG11201701139YA (en) 2017-03-30
KR102491439B1 (ko) 2023-01-25

Similar Documents

Publication Publication Date Title
JP7752150B2 (ja) アビラテロン酢酸エステル製剤
CN106687112A (zh) 醋酸阿比特龙制剂和使用方法
US9889144B2 (en) Abiraterone acetate formulation and methods of use
HK40020084B (zh) 乙酸阿比特龙酯制剂
HK40018807A (en) Abiraterone acetate formulation
HK40020084A (en) Abiraterone acetate formulation
HK1234990A1 (en) Abiraterone acetate formulation and methods of use
HK1220162B (en) Abiraterone acetate formulation
OA18485A (en) Abiraterone acetate formulation and methods of use.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1234990

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170517

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1234990

Country of ref document: HK